Chemical Namepralsetinib
Dosage FormCapsules (oral; 100 mg)
Drug ClassKinase inhibitors
CompanyBlueprint Medicines
Approval Year2020


  • To treat adult patients with non-small cell lung cancer (NSCLC) which has spread to other parts of the body (metastatic) and is caused by abnormal RET (rearranged during transfection) genes.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gavreto (pralsetinib) Prescribing Information. 2020Blueprint Medicines Corporation, Cambridge, MA
Document TitleYearSource
Treating Non-Small Cell Lung Cancer. 2020American Cancer Society